Treatment of MOG antibody associated disorders: results of an international survey

被引：78

作者：

Whittam, D. H. ^{[1
]}

Karthikeayan, V ^{[1
]}

Gibbons, E. ^{[1
]}

Kneen, R. ^{[2
]}

Chandratre, S. ^{[3
]}

Ciccarelli, O. ^{[4
]}

Hacohen, Y. ^{[4
,5
]}

de Seze, J. ^{[6
,7
]}

Deiva, K. ^{[8
]}

Hintzen, R. Q. ^{[9
]}

Wildemann, B. ^{[10
]}

Jarius, S. ^{[10
]}

Kleiter, I ^{[11
,12
]}

Rostasy, K. ^{[13
]}

Huppke, P. ^{[14
]}

Hemmer, B. ^{[15
,16
]}

Paul, F. ^{[17
,18
]}

Aktas, O. ^{[19
]}

Proebstel, A. K. ^{[20
,21
,22
]}

Arrambide, G. ^{[23
]}

Tintore, M. ^{[23
]}

Amato, M. P. ^{[24
,25
]}

Nosadini, M. ^{[26
]}

Mancardi, M. M. ^{[27
]}

Capobianco, M. ^{[28
,29
]}

Illes, Z. ^{[30
]}

Siva, A. ^{[31
]}

Altintas, A. ^{[32
]}

Akman-Demir, G. ^{[33
]}

Pandit, L. ^{[34
]}

Apiwattankul, M. ^{[35
]}

Hor, J. Y. ^{[36
]}

Viswanathan, S. ^{[37
]}

Qiu, W. ^{[38
]}

Kim, H. J. ^{[39
]}

Nakashima, I ^{[40
]}

Fujihara, K. ^{[41
,42
,43
]}

Ramanathan, S. ^{[44
,45
]}

Dale, R. C. ^{[44
,45
]}

Boggild, M. ^{[46
]}

Broadley, S. ^{[47
]}

Lana-Peixoto, M. A. ^{[48
]}

Sato, D. K. ^{[49
]}

Tenembaum, S. ^{[50
]}

Cabre, P. ^{[51
]}

Wingerchuk, D. M. ^{[52
]}

Weinshenker, B. G. ^{[53
]}

Greenberg, B. ^{[54
]}

Matiello, M. ^{[55
,56
]}

Klawiter, E. C. ^{[55
,56
]}

机构：

[1] Walton Ctr NHS Fdn Trust, Dept Neurol, Liverpool, Merseyside, England

[2] Alder Hey Childrens Hosp, Dept Paediat Neurol, Liverpool, Merseyside, England

[3] John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Oxford, England

[4] UCL Inst Neurol, Multiple Sclerosis Ctr, Queen Sq, London, England

[5] Great Ormond St Hosp Sick Children, Dept Paediat Neurol, London, England

[6] CHU Strasbourg, Hop Hautepiere, Dept Neurol, Strasbourg, France

[7] CHU Strasbourg, Hop Hautepiere, Clin Invest Ctr, Strasbourg, France

[8] CHU Paris Sud, Hop Bicetre, Dept Paediat Neurol, Le Kremlin Bicetre, France

[9] Erasmus MC, Dept Neurol, MS Ctr ErasMS, Rotterdam, Netherlands

[10] Heidelberg Univ, Dept Neurol, Mol Neuroimmunol Grp, Heidelberg, Germany

[11] Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, Bochum, Germany

[12] Behandlungszentrum Kempfenhausen Multiple Skleros, Marianne Str Klin, Berg, Germany

[13] Witten Herdrecke Univ, Childrens Hosp Datteln, Dept Paediat Neurol, Datteln, Germany

[14] Georg August Univ, Univ Med Ctr Gottingen, Dept Paediat & Paediat Neurol, Gottingen, Germany

[15] Tech Univ Munich, Sch Med, Dept Neurol, Munich, Germany

[16] Munich Cluster Syst Neurol SyNergy, Munich, Germany

[17] Charite Univ Med Berlin, NeuroCure Clin Res Ctr, Max Delbrueck Ctr Mol Med, Berlin, Germany

[18] Charite Univ Med Berlin, Expt & Clin Res Ctr, Max Delbrueck Ctr Mol Med, Berlin, Germany

[19] Heinrich Heine Univ Dusseldorf, Dept Neurol, D-40225 Dusseldorf, Germany

[20] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA

[21] Univ Calif San Francisco, Weill Inst Neurosci, San Francisco, CA 94143 USA

[22] Univ Basel, Univ Hosp Basel, Dept Med & Biomed, Neurol Clin & Policlin, Basel, Switzerland

[23] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Ctr Esclerosi Multiple Catalunya, Vall dHebron Inst Recerca,Serv Neurol Neuroimmuno, Barcelona, Spain

[24] Univ Florence, Dept NEUROFARBA, Neurosci Sect, Florence, Italy

[25] IRCCS Fdn Don Carlo Gnocchi, Florence, Italy

[26] Univ Hosp Padua, Dept Womens & Childrens Hlth, Paediat Neurol & Neurophysiol Unit, Padua, Italy

[27] IRCCS Giannina Gaslini Inst, Dept Med & Surg Neurosci & Rehabil, Genoa, Italy

[28] Univ Hosp San Luigi Gonzaga, Dept Neurol, Orbassano, Italy

[29] Univ Hosp San Luigi Gonzaga, Reg Multiple Sclerosis Ctr, Orbassano, Italy

[30] Odense Univ Hosp, Dept Neurol, Odense, Denmark

[31] Istanbul Univ, Dept Neurol, Cerrahpasa Sch Med, Istanbul, Turkey

[32] Koc Univ, Sch Med, Dept Neurol, Istanbul, Turkey

[33] Bilim Univ, Dept Neurol, Istanbul, Turkey

[34] Nitte Univ, Dept Neurol, Mangalore, Karnataka, India

[35] Minist Publ Hlth, Dept Neurol, Neuroimmunol Unit, Prasat Neurol Inst, Bangkok, Thailand

[36] Penang Gen Hosp, Dept Neurol, George Town, Malaysia

[37] Minist Hlth Malaysia, Dept Neurol, Kuala Lumpur Hosp, Kuala Lumpur, Malaysia

[38] Sun Yat Sen Univ, Dept Neurol, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China

[39] Natl Canc Ctr, Dept Neurol, Res Inst & Hosp, Goyang, South Korea

[40] Tohoku Med & Pharmaceut Univ, Dept Neurol, Sendai, Miyagi, Japan

[41] Fukushima Med Univ, Dept Multiple Sclerosis Therapeut, Sch Med, Koriyama, Fukushima, Japan

[42] Southern TOHOKU Res Inst Neurosci, Koriyama, Fukushima, Japan

[43] Southern TOHOKU Res Inst Neurosci STRINS, MS & NMO Ctr, Koriyama, Fukushima, Japan

[44] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia

[45] Childrens Hosp Westmead, Kids Neurosci Ctr, Neuroimmunol Grp, Sydney, NSW, Australia

[46] Townsville Hosp, Dept Neurol, Townsville, Qld, Australia

[47] Griffith Univ, Sch Med, Gold Coast Campus, Mt Gravatt, Qld, Australia

[48] Univ Fed Minas Gerais, CIEM MS Res Ctr, Med Sch, Belo Horizonte, MG, Brazil

[49] Pontificia Univ Catolica Rio Grande do Sul, Inst Cerebro Rio Grande do Sul InsCer, Porto Alegre, RS, Brazil

[50] Natl Pediat Hosp Dr Juan P Garrahan, Dept Neurol, Buenos Aires, DF, Argentina

来源：

JOURNAL OF NEUROLOGY | 2020年 / 267卷 / 12期

关键词：

Myelin oligodendrocyte glycoprotein; MOG; MOGAD; Survey; OLIGODENDROCYTE GLYCOPROTEIN ANTIBODIES; NEUROMYELITIS-OPTICA; CLINICAL SPECTRUM; DISEASE; ADULTS; IGG; ENCEPHALITIS; DIAGNOSIS; RESPONSES; CHILDREN;

D O I：

10.1007/s00415-020-10026-y

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Introduction While monophasic and relapsing forms of myelin oligodendrocyte glycoprotein antibody associated disorders (MOGAD) are increasingly diagnosed world-wide, consensus on management is yet to be developed. Objective To survey the current global clinical practice of clinicians treating MOGAD. Method Neurologists worldwide with expertise in treating MOGAD participated in an online survey (February-April 2019). Results Fifty-two responses were received (response rate 60.5%) from 86 invited experts, comprising adult (78.8%, 41/52) and paediatric (21.2%, 11/52) neurologists in 22 countries. All treat acute attacks with high dose corticosteroids. If recovery is incomplete, 71.2% (37/52) proceed next to plasma exchange (PE). 45.5% (5/11) of paediatric neurologists use IV immunoglobulin (IVIg) in preference to PE. Following an acute attack, 55.8% (29/52) of respondents typically continue corticosteroids for >= 3 months; though less commonly when treating children. After an index event, 60% (31/51) usually start steroid-sparing maintenance therapy (MT); after >= 2 attacks 92.3% (48/52) would start MT. Repeat MOG antibody status is used by 52.9% (27/51) to help decide on MT initiation. Commonly used first line MTs in adults are azathioprine (30.8%, 16/52), mycophenolate mofetil (25.0%, 13/52) and rituximab (17.3%, 9/52). In children, IVIg is the preferred first line MT (54.5%; 6/11). Treatment response is monitored by MRI (53.8%; 28/52), optical coherence tomography (23.1%; 12/52) and MOG antibody titres (36.5%; 19/52). Regardless of monitoring results, 25.0% (13/52) would not stop MT. Conclusion Current treatment of MOGAD is highly variable, indicating a need for consensus-based treatment guidelines, while awaiting definitive clinical trials.

引用

页码：3565 / 3577

页数：13

共 50 条

[1] Treatment of MOG antibody associated disorders: results of an international survey
D. H. Whittam
V. Karthikeayan
E. Gibbons
R. Kneen
S. Chandratre
O. Ciccarelli
Y. Hacohen
J. de Seze
K. Deiva
R. Q. Hintzen
B. Wildemann
S. Jarius
I. Kleiter
K. Rostasy
P. Huppke
B. Hemmer
F. Paul
O. Aktas
A. K. Pröbstel
G. Arrambide
M. Tintore
M. P. Amato
M. Nosadini
M. M. Mancardi
M. Capobianco
Z. Illes
A. Siva
A. Altintas
G. Akman-Demir
L. Pandit
M. Apiwattankul
J. Y. Hor
S. Viswanathan
W. Qiu
H. J. Kim
I. Nakashima
K. Fujihara
S. Ramanathan
R. C. Dale
M. Boggild
S. Broadley
M. A. Lana-Peixoto
D. K. Sato
S. Tenembaum
P. Cabre
D. M. Wingerchuk
B. G. Weinshenker
B. Greenberg
M. Matiello
E. C. Klawiter
Journal of Neurology, 2020, 267 : 3565 - 3577
[2] Treatment of MOG antibody associated disorders: results of an international survey
Whittam, D. H.
Chandratre, S.
Ciccarelli, O.
de Seze, J.
Deiva, K.
Hintzen, R. Q.
Wildemann, B.
Jarius, S.
Kleiter, I.
Rostasy, K.
Huppke, P.
Hemmer, B.
Paul, F.
Probstel, A. K.
Tintore, M.
Amato, M. P.
Nosadini, M.
Mancardi, M. M.
Capobianco, M.
Illes, Z.
Siva, A.
Altintas, A.
Akman-Demir, G.
Pandit, L.
Apiwattankul, M.
Hor, J. Y.
Viswanathan, S.
Qiu, W.
Fujihara, K.
Ramanathan, S.
Dale, R. C.
Boggild, M.
Broadley, S.
Lana-Peixoto, M. A.
Tenembaum, S.
Cabre, P.
Wingerchuk, D. M.
Greenberg, B.
Weinshenker, B. G.
Klawiter, E. C.
Bennett, J. L.
Wallach, A. I.
Kister, I.
Banwell, B. L.
Traboulsee, A.
Pohl, D.
Palace, J.
Leite, M. I.
Marignier, R.
Jacob, A.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 369 - 371
[3] Significance of CSF MOG antibody testing in MOG antibody associated disorders
Matsumoto, Y.
Tatsuro, M.
Kaneko, K.
Takahashi, T.
Namatame, C.
Ono, H.
Takai, Y.
Kuroda, H.
Nakashima, I.
Fujihara, K.
Aoki, M.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 776 - 777
[4] Features of MOG required for recognition by patients with MOG antibody-associated disorders
Macrini, Caterina
Gerhards, Ramona
Winklmeier, Stephan
Bergmann, Lena
Mader, Simone
Spadaro, Melania
Vural, Atay
Smolle, Michaela
Hohlfeld, Reinhard
Kuempfel, Tania
Lichtenthaler, Stefan F.
Franquelim, Henri G.
Jenne, Dieter
Meinl, Edgar
BRAIN, 2021, 144 : 2375 - 2389
[5] Anti MOG antibody associated disorders in Pakistan: A retrospective audit
Mohammad, Tahira
Ahmad, Arsalan
Ahmed, Tahir
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
[6] Anti MOG antibody associated neurological disorders: a retrospective audit
Qayyum, F.
Sheikh, S.
Ahmad, A.
Ahmed, T.
Awan, S.
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
[7] Optic neuropathy in anti-mog antibody associated disorders
Laassila, S.
Bouchal, S.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 471 - 471
[8] Clinical and imaging predictors of MOG-antibody persistency in pediatric MOG-associated disorders
Chavez, E. Martinez
Zakzouk, R.
Amirabadi, A.
Yea, C.
Yeh, A.
Branson, H.
Longoni, G.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 174 - 174
[9] Predictors of Diagnosis and Outcome in Pediatric MOG-antibody Associated Disorders
Hardy, Duriel
McGuire, Jennifer
Banwell, Brenda
Hopkins, Sarah
NEUROLOGY, 2020, 94 (15)
[10] Blood parameter analysis in pediatric MOG-antibody-associated disorders
Peternell, A.
Breu, M.
Preisel, M.
Schimmel, M.
Eisenkoelbl, A.
Zobel, J.
Wendel, E. -M.
Reindl, M.
Rostasy, K.
Baumann, M.
Lechner, C.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 527 - 527

← 1 2 3 4 5 →